Alpha Tau Medical Ltd.

NASDAQ:DRTS

Biotechnology

Healthcare
$12.01 +0.42%

+$0.04 today

Market cap
$1.11B
Beta
1.20
P/E (TTM)
-15.2
EPS (TTM)
-$0.63
52W Low $2.85High $11.62

Volume 0.64M

Average 0.69M

DRTS Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Alpha Tau Medical Ltd.NASDAQ: DRTS

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 42.2% from a year ago

Net receivables stood at $1.12M at the end of Q1 FY2026, down 42.2% from a year earlier and up 3013.9% from the prior quarter. Over 3 fiscal years it compounded at +4.0% a year.

Context

  • Net receivables amounted to 1.0% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -42.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.12M+3013.9% QoQ
Last fiscal yearDec 2025
$36K-89.2% YoY
Year agoMar 2025
$1.94M-42.2% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.2%——
1 year-89.2%——
3-year CAGR+4.0%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
36K USD
Year-over-year change
-89.2%
4-year CAGR
-47.7%

Net Receivables vs competitors

How DRTS compares with its peers on the latest reported figures

  • DRTS's Mar 2026 net receivables of $1.12M is the 2nd highest of the 3 companies compared; the peer median is $1.13M.
  • Its year-over-year change of -42.2% is the lowest of 2, against a peer median of -25.6%.
  • Net receivables amounts to 1.0% of total assets for DRTS, versus a peer median of 0.2%.
DRTS Competitors Peer median
Net Receivables for DRTS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AKTSAktis Oncology, Inc.Mar 2026$2.2M ——0.4%
DRTSAlpha Tau Medical Ltd.Mar 2026$1.12M -42.2%+4.0%1.0%
CATXPerspective Therapeutics, Inc.Mar 2026$58K -25.6%-83.6%0.0%
Peer median (excluding DRTS) $1.13M-25.6%-83.6%0.2%

Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents23.24M5.84M12.66M13.72M15.98M
Short-term Investments8.08M98.69M69.13M45.88M60.92M
Net Receivables480K32K19K332K36K
Inventory(8.17M)0(19K)00
Other Current Assets8.79M1.13M3.5M3.26M0
Total Current Assets32.64M106.48M85.76M64.23M78.3M
Property, Plant & Equipment (Net)7.55M13.28M21.16M21.54M26.88M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets0000928K
Other Non-current Assets2.03M391K471K432K479K
Total Non-current Assets9.57M13.67M21.63M21.98M28.28M
Total Assets42.22M120.15M107.39M86.2M106.58M
Account Payables1.2M1.42M2.57M3.53M3.87M
Short-term Debt001.06M1.01M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.41M1.34M(983K)389K3.78M
Total Current Liabilities4.41M4.34M7.1M8.68M10.51M
Long-term Debt53.96M05.61M5.56M6.35M
Deferred Tax Liabilities00001.02M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities18.62M5.63M3.6M3.34M5.35M
Total Non-current Liabilities72.59M10.15M15.81M14.86M18.97M
Total Liabilities76.99M14.49M22.91M23.54M29.48M
Common Stock00000
Retained Earnings(52.84M)(86.6M)(115.76M)(147.51M)(190.14M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(34.78M)105.66M84.48M62.67M77.1M
Total Debt53.96M5.19M13.28M12.54M13.73M
Net Debt30.73M(643K)619K(1.19M)(2.25M)

Alpha Tau Medical Ltd.

NASDAQ:DRTS

Intrinsic Alpha fair value

Locked

Current Price

$12.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.